Skip to main content
SpringerLink
Log in
Book cover

Hepatitis C Virus Disease pp 168–191Cite as

Interferon-Based Therapy for Hepatitis C Virus Infections

  • Chapter

  • 660 Accesses

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Bodenheimer, H.C., Jr., Lindsay, K.L., Davis, G.L., Lewis, J.H., Thung, S.N., Seeff, L.B. (1997). Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology, 26: 473–477.

    PubMed  CAS  Google Scholar 

  • Bressler, B.L., Guindi, M., Tomlinson, G., Heathcote, J. (2003). High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology, 38: 639–644.

    PubMed  CAS  Google Scholar 

  • Bruchfeld, A., Lindahl, K., Schvarcz, R., Stahle, L. (2002). Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis. Therapeutic Drug Monitoring, 24: 701–708.

    PubMed  CAS  Google Scholar 

  • Bukh, J., Miller, R.H., Purcell, R.H. (1995). Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Seminars in Liver Disease, 15: 41–63.

    PubMed  CAS  Google Scholar 

  • Carithers, R.L., Jr., Emerson, S.S. (1997). Therapy of hepatitis C: meta-analysis of interferon alpha-2b trials. Hepatology, 26: 83S–88S.

    PubMed  CAS  Google Scholar 

  • Carrat, F., Bani-Sadr, F., Pol, S., Rosenthal, E., Lunel-Fabiani, F., Benzekri, A., Morand, P., Goujard, C., Pialoux, G., Piroth, L., Salmon-Ceron, D., Degott, C., Cacoub, P., Perronne, C. (2004). Pegylated interferon alpha-2b vs standard interferon alpha-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. Journal of the American Medical Association, 292: 2839–2848.

    PubMed  CAS  Google Scholar 

  • Chen, L., Borozan, I., Feld, J., Sun, J., Tannis, L.L., Coltescu, C., Heathcote, J., Edwards, A.M., McGilvray, I.D. (2005). Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology, 128: 1437–1444.

    PubMed  CAS  Google Scholar 

  • Chuang, W.L., Dai, C.Y., Chen, S.C., Lee, L.P., Lin, Z.Y., Hsieh, M.Y., Wang, L.Y., Yu, M.L., Chang, W.Y. (2004). Randomized trial of three different regimens for 24 weeks for re-treatment of chronic hepatitis C patients who failed to respond to interferon-alpha monotherapy in Taiwan. Liver International, 24: 595–602.

    PubMed  CAS  Google Scholar 

  • Chuang, W.L., Dai, C.Y., Chang, W.Y., Lee, L.P., Lin, Z.Y., Chen, S.C., Hsieh, M.Y., Wang, L.Y., Yu, M.L. (2005). Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy. Antiviral Therapy, 10: 125–133.

    PubMed  CAS  Google Scholar 

  • Chung, R.T., Andersen, J., Volberding, P., Robbins, G.K., Liu, T., Sherman, K.E., Peters, M.G., Koziel, M.J., Bhan, A.K., Alston, B., Colquhoun, D., Nevin, T., Harb, G., van der Horst, C. (2004). Peginterferon alpha-2a plus ribavirin versus interferon alpha-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. New England Journal of Medicine, 351: 451–459.

    PubMed  CAS  Google Scholar 

  • Cramp, M.E., Rossol, S., Chokshi, S., Carucci, P., Williams, R., Naoumov, N.V. (2000). Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology, 118: 346–355.

    PubMed  CAS  Google Scholar 

  • Crotty, S., Maag, D., Arnold, J.J., Zhong, W., Lau, J.Y., Hong, Z., Andino, R., Cameron, C.E. (2000). The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nature Medicine, 6: 1375–1379.

    PubMed  CAS  Google Scholar 

  • D’Souza, R., Sabin, C.A., Foster, G.R. (2005). Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. American Journal of Gastroenterology, 100: 1509–1515.

    PubMed  CAS  Google Scholar 

  • Dai, C.Y., Chuang, W.L., Chang, W.Y., Chen, S.C., Lee, L.P., Hsieh, M.Y., Hou, N.J., Lin, Z.Y., Hsieh, M.Y., Wang, L.Y., Yu, M.L. (2005). Polymorphisms in the interferon-gamma gene at position +874 in patients with chronic hepatitis C treated with high-dose interferon-alpha and ribavirin. Antiviral Research, 67: 93–97.

    PubMed  CAS  Google Scholar 

  • Dai, C.Y., Chuang, W.L., Chang, W.Y., Chen, S.C., Lee, L.P., Hsieh, M.Y., Hou, N.J., Lin, Z.Y., Huang, J.F., Hsieh, M.Y., Wang, L.Y., Yu, M.L. (2006). Tumor necrosis factor- alpha promoter polymorphism at position -308 predicts response to combination therapy in hepatitis C virus infection. Journal of Infectious Disease, 193: 98–101.

    CAS  Google Scholar 

  • Dalgard, O., Bjoro, K., Hellum, K.B., Myrvang, B., Ritland, S., Skaug, K., Raknerud, N., Bell, H. (2004). Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology, 40: 1260–1265.

    PubMed  CAS  Google Scholar 

  • Davis, G.L., Balart, L.A., Schiff, E.R., Lindsay, K., Bodenheimer, H.C., Jr., Perrillo, R.P., Carey, W., Jacobson, I.M., Payne, J., Dienstag, J.L., et al. (1989). Treatment of chronic hepatitis C with recombinant interferon alpha. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. New England Journal of Medicine, 321: 1501–1506.

    PubMed  CAS  Google Scholar 

  • Davis, G.L., Lau, J.Y. (1995). Choice of appropriate end points of response to interferon therapy in chronic hepatitis C virus infection. Journal of Hepatology, 22: 110–114.

    PubMed  CAS  Google Scholar 

  • Davis, G. L. (2002). Monitoring of viral levels during therapy of hepatitis C. Hepatology, 36: S145–151.

    PubMed  Google Scholar 

  • Davis, G.L., Wong, J.B., McHutchison, J.G., Manns, M.P., Harvey, J., Albrecht, J. (2003). Early virologic response to treatment with peginterferon alpha-2b plus ribavirin in patients with chronic hepatitis C. Hepatology, 38: 645–652.

    PubMed  CAS  Google Scholar 

  • Di Bisceglie A.M., Hoofnagle, J.H. (2002). Optimal therapy of hepatitis C. Hepatology, 36: S121–127.

    Google Scholar 

  • Di Bisceglie, A.M., Martin, P., Kassianides, C., Lisker-Melman, M., Murray, L., Waggoner, J., Goodman, Z., Banks, S.M., Hoofnagle, J.H. (1989). Recombinant interferon alpha therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. New England Journal of Medicine, 321: 1506–1510.

    PubMed  Google Scholar 

  • Dixit, N.M., Layden-Almer, J.E., Layden, T.J., Perelson, A.S. (2004). Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature, 432: 922–924.

    PubMed  CAS  Google Scholar 

  • EASL International Consensus Conference on Hepatitis C. Paris, 26-27 February 1999. Consensus statement. Journal of Hepatology, 31 Suppl. 1: 3–8.

    Google Scholar 

  • el-Sayed, H.F., Abaza, S.M., Mehanna, S., Winch, P.J. (1997). The prevalence of hepatitis B and C infections among immigrants to a newly reclaimed area endemic for Schistosoma mansoni in Sinai, Egypt. Acta Tropica, 68: 229–237.

    PubMed  CAS  Google Scholar 

  • Enomoto, N., Sakuma, I., Asahina, Y., Kurosaki, M., Murakami, T., Yamamoto, C., Ogura, Y., Izumi, N., Marumo, F., Sato, C. (1996). Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. New England Journal of Medicine, 334: 77–81.

    PubMed  CAS  Google Scholar 

  • Feld, J.J., Hoofnagle, J.H. (2005). Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature, 436: 967–972.

    PubMed  CAS  Google Scholar 

  • Fried, M.W., Shiffman, M.L., Reddy, K.R., Smith, C., Marinos, G., Goncales, F.L., Jr., Haussinger, D., Diago, M., Carosi, G., Dhumeaux, D., Craxi, A., Lin, A., Hoffman, J., Yu, J. (2002). Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine, 347: 975–982.

    PubMed  CAS  Google Scholar 

  • Hadziyannis, S.J., Sette, H., Jr., Morgan, T.R., Balan, V., Diago, M., Marcellin, P., Ramadori, G., Bodenheimer, H., Jr., Bernstein, D., Rizzetto, M., Zeuzem, S., Pockros, P.J., Lin, A., Ackrill, A.M. (2004). Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Annals of Internal Medicine, 140: 346–355.

    PubMed  CAS  Google Scholar 

  • Heathcote, E.J., Shiffman, M.L., Cooksley, W.G., Dusheiko, G.M., Lee, S.S., Balart, L., Reindollar, R., Reddy, R.K., Wright, T.L., Lin, A., Hoffman, J., De Pamphilis, J. (2000). Peginterferon alpha-2a in patients with chronic hepatitis C and cirrhosis. New England Journal of Medicine, 343: 1673–1680.

    PubMed  CAS  Google Scholar 

  • Hepburn, M.J., Hepburn, L.M., Cantu, N.S., Lapeer, M.G., Lawitz, E.J. (2004). Differences in treatment outcome for hepatitis C among ethnic groups. American Journal of Medicine, 117: 163–168.

    PubMed  CAS  Google Scholar 

  • Hickman, I.J., Clouston, A.D., Macdonald, G.A., Purdie, D.M., Prins, J.B., Ash, S., Jonsson, J.R., Powell, E.E. (2002). Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut, 51: 89–94.

    PubMed  CAS  Google Scholar 

  • Hickman, I.J., Powell, E.E., Prins, J.B., Clouston, A.D., Ash, S., Purdie, D.M., Jonsson, J.R. (2003). In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy. Journal of Hepatology, 39: 1042–1048.

    PubMed  CAS  Google Scholar 

  • Hoofnagle, J.H., Mullen, K.D., Jones, D.B., Rustgi, V., Di Bisceglie, A., Peters, M., Waggoner, J.G., Park, Y., Jones, E.A. (1986). Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report. New England Journal of Medicine, 315: 1572–1578.

    Google Scholar 

  • Hung, C.H., Lee, C.M., Lu, S.N., Lee, J.F., Wang, J.H., Tung, H.D., Chen, T.M., Hu, T.H., Chen, W.J., Changchien, C.S. (2003). Mutations in the NS5A and E2-PePHD region of hepatitis C virus type 1b and correlation with the response to combination therapy with interferon and ribavirin. Journal of Viral Hepatitis, 10: 87–94.

    PubMed  Google Scholar 

  • Hwang, Y., Chen, E.Y., Gu, Z.J., Chuang, W.L., Yu, M.L., Lai, M.Y., Chao, Y. ., Lee, C. ., Wang, J.H., Dai, C.Y., Shian-Jy Bey, M., Liao, Y.T., Chen, P.J., Chen, D.S. (2006). Genetic predisposition of responsiveness to therapy for chronic hepatitis C. Pharmacogenomics, 7: 697–709.

    PubMed  CAS  Google Scholar 

  • International Interferon-Alpha Hepatocellular Carcinoma Study Group (1998). Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet, 351: 1535–1539.

    Google Scholar 

  • Jaeckel, E., Cornberg, M., Wedemeyer, H., Santantonio, T., Mayer, J., Zankel, M., Pastore, G., Dietrich, M., Trautwein, C., Manns, M.P. (2001). Treatment of acute hepatitis C with interferon alpha-2b. New England Journal of Medicine, 345: 1452–1457.

    PubMed  CAS  Google Scholar 

  • Jensen, D.M., Morgan, T.R., Marcellin, P., Pockros, P.J., Reddy, K.R., Hadziyannis, S.J., Ferenci, P., Ackrill, A.M., Willems, B. (2006). Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology, 43: 954–960.

    PubMed  CAS  Google Scholar 

  • Jian Wu, Y., Shu Chen, L., Gui Qiang, W. (2006). Effects of fatty liver and related factors on the efficacy of combination antiviral therapy in patients with chronic hepatitis C. Liver International, 26: 166–172.

    PubMed  Google Scholar 

  • Kamal, S.M., Fehr, J., Roesler, B., Peters, T., Rasenack, J.W. (2002). Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C. Gastroenterology, 123: 1070–1083.

    PubMed  CAS  Google Scholar 

  • Kamal, S.M., Fouly, A.E., Kamel, R.R., Hockenjos, B., Al Tawil, A., Khalifa, K.E., He, Q., Koziel, M.J., El Naggar, K.M., Rasenack, J., Afdhal, N.H. (2006). Peginterferon alpha-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology, 130: 632–638.

    PubMed  CAS  Google Scholar 

  • Kelleher, T. B., Afdhal, N. (2005). Maintenance therapy for chronic hepatitis C. Current Gastroenterology Reports, 7: 50–53.

    PubMed  Google Scholar 

  • Kjaergard, L.L., Krogsgaard, K., Gluud, C. (2001). Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials. British Medical Journal, 323: 1151–1155.

    PubMed  CAS  Google Scholar 

  • Konishi, I., Horiike, N., Hiasa, Y., Michitaka, K., Onji, M. (2004). CCR5 promoter polymorphism influences the interferon response of patients with chronic hepatitis C in Japan. Intervirology, 47: 114–120.

    PubMed  CAS  Google Scholar 

  • Lai, M.Y., Kao, J.H., Yang, P.M., Wang, J.T., Chen, P.J., Chan, K.W., Chu, J.S., Chen, D.S. (1996). Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology, 111: 1307–1312.

    PubMed  CAS  Google Scholar 

  • Lau, D.T., Kleiner, D.E., Ghany, M.G., Park, Y., Schmid, P., Hoofnagle, J.H. (1998). 10-year follow-up after interferon-alpha therapy for chronic hepatitis C. Hepatology, 28: 1121–1127.

    PubMed  CAS  Google Scholar 

  • Lau, J.Y., Tam, R.C., Liang, T.J., Hong, Z. (2002). Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology, 35: 1002–1009.

    PubMed  CAS  Google Scholar 

  • Layden, J.E., Layden, T.J. (2001). How can mathematics help us understand HCV? Gastroenterology, 120: 1546–1549.

    PubMed  CAS  Google Scholar 

  • Lee, S.D., Yu, M.L., Cheng, P.N., Lai, M.Y., Chao, Y.C., Hwang, S.J., Chang, W.Y., Chang, T.T., Hsieh, T.Y., Liu, C.J., Chen, D.S. (2005). Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan. Journal of Viral Hepatitis, 12: 283–291.

    PubMed  Google Scholar 

  • Liaw, Y.F., Chen, Y.C., Sheen, I.S., Chien, R.N., Yeh, C.T., Chu, C.M. (2004). Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. Gastroenterology, 126: 1024–1029.

    PubMed  Google Scholar 

  • Lindahl, K., Stahle, L., Bruchfeld, A., Schvarcz, R. (2005). High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology, 41: 275–279.

    PubMed  CAS  Google Scholar 

  • Lindsay, K.L., Trepo, C., Heintges, T., Shiffman, M.L., Gordon, S.C., Hoefs, J.C., Schiff, E.R., Goodman, Z.D., Laughlin, M., Yao, R., Albrecht, J.K. (2001). A randomized, double-blind trial comparing pegylated interferon alpha-2b to interferon alpha-2b as initial treatment for chronic hepatitis C. Hepatology, 34: 395–403.

    PubMed  CAS  Google Scholar 

  • Liu, C.J., Chen, P.J., Lai, M.Y., Kao, J.H., Jeng, Y.M., Chen, D.S. (2003). Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. Hepatology, 37: 568–576.

    PubMed  CAS  Google Scholar 

  • Liu, C.J., Liou, J.M., Chen, D.S., Chen, P.J. (2005). Natural course and treatment of dual hepatitis B virus and hepatitis C virus infections. Journal of the Formosan Medical Association, 104: 783–791.

    PubMed  Google Scholar 

  • Mangia, A., Santoro, R., Minerva, N., Ricci, G.L., Carretta, V., Persico, M., Vinelli, F., Scotto, G., Bacca, D., Annese, M., Romano, M., Zechini, F., Sogari, F., Spirito, F., Andriulli, A. (2005). Peginterferon alpha-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. New England Journal of Medicine, 352: 2609–2617.

    PubMed  CAS  Google Scholar 

  • Manns, M.P., McHutchison, J.G., Gordon, S.C., Rustgi, V.K., Shiffman, M., Reindollar, R., Goodman, Z.D., Koury, K., Ling, M., Albrecht, J.K. (2001). Peginterferon alpha-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet, 358: 958–965.

    PubMed  CAS  Google Scholar 

  • Marcellin, P., Boyer, N., Gervais, A., Martinot, M., Pouteau, M., Castelnau, C., Kilani, A., Areias, J., Auperin, A., Benhamou, J.P., Degott, C., Erlinger, S. (1997). Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Annals of Internal Medicine, 127: 875–881.

    PubMed  CAS  Google Scholar 

  • Martinot-Peignoux, M., Marcellin, P., Pouteau, M., Castelnau, C., Boyer, N., Poliquin, M., Degott, C., Descombes, I., Le Breton, V., Milotova, V., et al. (1995). Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alpha therapy in chronic hepatitis C. Hepatology, 22: 1050–1056.

    PubMed  CAS  Google Scholar 

  • McHutchison, J.G., Gordon, S.C., Schiff, E.R., Shiffman, M.L., Lee, W.M., Rustgi, V.K., Goodman, Z.D., Ling, M.H., Cort, S., Albrecht, J.K. (1998). Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. New England Journal of Medicine, 339: 1485–1492.

    PubMed  CAS  Google Scholar 

  • McHutchison, J.G., Poynard, T. (1999). Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Seminars in Liver Disease, 19 Suppl. 1: 57–65.

    PubMed  CAS  Google Scholar 

  • McHutchison, J.G., Poynard, T., Pianko, S., Gordon, S.C., Reid, A.E., Dienstag, J., Morgan, T., Yao, R., Albrecht, J. (2000). The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group. Gastroenterology, 119: 1317–1323.

    PubMed  CAS  Google Scholar 

  • McHutchison, J.G., Manns, M., Patel, K., Poynard, T., Lindsay, K.L., Trepo, C., Dienstag, J., Lee, W.M., Mak, C., Garaud, J.J., Albrecht, J.K. (2002a). Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology, 123: 1061–1069.

    CAS  Google Scholar 

  • McHutchison, J.G., Poynard, T., Esteban-Mur, R., Davis, G.L., Goodman, Z.D., Harvey, J., Ling, M.H., Garaud, J.J., Albrecht, J.K., Patel, K., Dienstag, J.L., Morgan, T. (2002b). Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin. Hepatology, 35: 688–693.

    CAS  Google Scholar 

  • Moribe, T., Hayashi, N., Kanazawa, Y., Mita, E., Fusamoto, H., Negi, M., Kaneshige, T., Igimi, H., Kamada, T., Uchida, K. (1995). Hepatitis C viral complexity detected by single-strand conformation polymorphism and response to interferon therapy. Gastroenterology, 108: 789–795.

    PubMed  CAS  Google Scholar 

  • Muir, A.J., Bornstein, J.D., Killenberg, P.G. (2004). Peginterferon alpha-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. New England Journal of Medicine, 350: 2265–2271.

    PubMed  CAS  Google Scholar 

  • National Institutes of Health Consensus Development Conference Panel (1997). Panel statement: management of hepatitis C. Hepatology, 26: 2S–10S.

    Google Scholar 

  • National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002—June 10-12, 2002. Hepatology, 36: S3–20.

    Google Scholar 

  • Neumann, A.U., Lam, N.P., Dahari, H., Gretch, D.R., Wiley, T.E., Layden, T.J., Perelson, A.S. (1998). Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science, 282: 103–107.

    PubMed  CAS  Google Scholar 

  • Neumann, A.U., Lam, N.P., Dahari, H., Davidian, M., Wiley, T.E., Mika, B.P., Perelson, A.S., Layden, T.J. (2000). Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. Journal of Infectious Disease, 182: 28–35.

    CAS  Google Scholar 

  • Niederau, C., Heintges, T., Haussinger, D. (1996). Treatment of chronic hepatitis C with a-interferon: an analysis of the literature. Hepatogastroenterology, 43: 1544–1556.

    PubMed  CAS  Google Scholar 

  • Ohnishi, K., Matsuo, S., Matsutani, K., Itahashi, M., Kakihara, K., Suzuki, K., Ito, S., Fujiwara, K. (1996). Interferon therapy for chronic hepatitis C in habitual drinkers: comparison with chronic hepatitis C in infrequent drinkers. American Journal of Gastroenterology, 91: 1374–1379.

    PubMed  CAS  Google Scholar 

  • Okada, S., Akahane, Y., Suzuki, H., Okamoto, H., Mishiro, S. (1992). The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients. Hepatology, 16: 619–624.

    PubMed  CAS  Google Scholar 

  • Pascu, M., Martus, P., Hohne, M., Wiedenmann, B., Hopf, U., Schreier, E., Berg, T. (2004). Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences. Gut, 53: 1345–1351.

    PubMed  CAS  Google Scholar 

  • Perez-Olmeda, M., Nunez, M., Romero, M., Gonzalez, J., Castro, A., Arribas, J.R., Pedreira, J., Barreiro, P., Garcia-Samaniego, J., Martin-Carbonero, L., Jimenez-Nacher, I., Soriano, V. (2003). Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS, 17: 1023–1028.

    PubMed  CAS  Google Scholar 

  • Poynard, T., Leroy, V., Cohard, M., Thevenot, T., Mathurin, P., Opolon, P., Zarski, J.P. (1996). Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology, 24: 778–789.

    PubMed  CAS  Google Scholar 

  • Poynard, T., Marcellin, P., Lee, S.S., Niederau, C., Minuk, G.S., Ideo, G., Bain, V., Heathcote, J., Zeuzem, S., Trepo, C., Albrecht, J. (1998). Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet, 352: 1426–1432.

    PubMed  CAS  Google Scholar 

  • Poynard, T., McHutchison, J., Manns, M., Trepo, C., Lindsay, K., Goodman, Z., Ling, M.H., Albrecht, J. (2002). Impact of pegylated interferon alpha-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology, 122: 1303–1313.

    PubMed  CAS  Google Scholar 

  • Reddy, K.R., Hoofnagle, J.H., Tong, M.J., Lee, W.M., Pockros, P., Heathcote, E.J., Albert, D., Joh, T. (1999). Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology, 30: 787–793.

    PubMed  CAS  Google Scholar 

  • Reddy, K.R., Wright, T.L., Pockros, P.J., Shiffman, M., Everson, G., Reindollar, R., Fried, M.W., Purdum, P.P., 3rd, Jensen, D., Smith, C., Lee, W.M., Boyer, T.D., Lin, A., Pedder, S., DePamphilis, J. (2001). Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology, 33: 433–438.

    PubMed  CAS  Google Scholar 

  • Reichard, O., Norkrans, G., Fryden, A., Braconier, J.H., Sonnerborg, A., Weiland, O. (1998). Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet, 351: 83–87.

    PubMed  CAS  Google Scholar 

  • Romero-Gomez, M., Del Mar Viloria, M., Andrade, R.J., Salmeron, J., Diago, M., Fernandez-Rodriguez, C.M., Corpas, R., Cruz, M., Grande, L., Vazquez, L., Munoz-De-Rueda, P., Lopez-Serrano, P., Gila, A., Gutierrez, M.L., Perez, C., Ruiz-Extremera, A., Suarez, E., Castillo, J. (2005). Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology, 128: 636–641.

    PubMed  CAS  Google Scholar 

  • Schalm, S.W., Hansen, B.E., Chemello, L., Bellobuono, A., Brouwer, J.T., Weiland, O., Cavalletto, L., Schvarcz, R., Ideo, G., Alberti, A. (1997). Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. Journal of Hepatology, 26: 961–966.

    PubMed  CAS  Google Scholar 

  • Schalm, S.W., Weiland, O., Hansen, B.E., Milella, M., Lai, M.Y., Hollander, A., Michielsen, P.P., Bellobuono, A., Chemello, L., Pastore, G., Chen, D.S., Brouwer, J.T. (1999). Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis. Gastroenterology, 117: 408–413.

    PubMed  CAS  Google Scholar 

  • Sen, G.C. (2001). Viruses and interferons. Annual Review of Microbiology, 55: 255–281.

    PubMed  CAS  Google Scholar 

  • Sherman, M., Yoshida, E.M., Deschenes, M., Krajden, M., Bain, V.G., Peltekian, K., Anderson, F., Kaita, K., Simonyi, S., Balshaw, R., Lee, S.S. (2006). Peginterferon alpha-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy. Gut, 55: 1631–1638.

    PubMed  CAS  Google Scholar 

  • Shiffman, M.L. (2002). Retreatment of patients with chronic hepatitis C. Hepatology, 36: S128–134.

    PubMed  Google Scholar 

  • Shiffman, M.L. (2004). Retreatment of patients who do not respond to initial therapy for chronic hepatitis C. Cleveland Clinic Journal of Medicine, 71 Suppl. 3: S13–16.

    PubMed  Google Scholar 

  • Shiffman, M.L., Di Bisceglie, A.M., Lindsay, K.L., Morishima, C., Wright, E.C., Everson, G.T., Lok, A.S., Morgan, T.R., Bonkovsky, H.L., Lee, W.M., Dienstag, J.L., Ghany, M.G., Goodman, Z.D., Everhart, J.E. (2004). Peginterferon alpha-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology, 126: 1015–1023.

    PubMed  CAS  Google Scholar 

  • Shiratori, Y., Ito, Y., Yokosuka, O., Imazeki, F., Nakata, R., Tanaka, N., Arakawa, Y., Hashimoto, E., Hirota, K., Yoshida, H., Ohashi, Y., Omata, M. (2005). Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Annals of Internal Medicine, 142: 105–114.

    PubMed  CAS  Google Scholar 

  • Strader, D.B., Wright, T., Thomas, D.L., Seeff, L.B. (2004). Diagnosis, management, and treatment of hepatitis C. Hepatology, 39: 1147–1171.

    PubMed  Google Scholar 

  • Sugimoto, Y., Kuzushita, N., Takehara, T., Kanto, T., Tatsumi, T., Miyagi, T., Jinushi, M., Ohkawa, K., Horimoto, M., Kasahara, A., Hori, M., Sasaki, Y., Hayashi, N. (2002). A single nucleotide polymorphism of the low molecular mass polypeptide 7 gene influences the interferon response in patients with chronic hepatitis C. Journal of Viral Hepatitis, 9: 377–384.

    PubMed  CAS  Google Scholar 

  • Suzuki, F., Arase, Y., Suzuki, Y., Tsubota, A., Akuta, N., Hosaka, T., Someya, T., Kobayashi, M., Saitoh, S., Ikeda, K., Kobayashi, M., Matsuda, M., Takagi, K., Satoh, J., Kumada, H. (2004). Single nucleotide polymorphism of the MxA gene promoter influences the response to interferon monotherapy in patients with hepatitis C viral infection. Journal of Viral Hepatitis, 11: 271–276.

    PubMed  CAS  Google Scholar 

  • Tabone, M., Sidoli, L., Laudi, C., Pellegrino, S., Rocca, G., Della Monica, P., Fracchia, M., Galatola, G., Molinaro, G.C., Arico, S., Pera, A. (2002). Alcohol abstinence does not offset the strong negative effect of lifetime alcohol consumption on the outcome of interferon therapy. Journal of Viral Hepatitis, 9: 288–294.

    PubMed  CAS  Google Scholar 

  • Tang, J., Kaslow, R.A. (2004). Pharmacogenomic perspectives of chronic hepatitis C virus (HCV) infection. Pharmacogenomics Journal, 4: 171–174.

    PubMed  CAS  Google Scholar 

  • Thomas, D.L. (2002). Hepatitis C and human immunodeficiency virus infection. Hepatology, 36: S201–209.

    PubMed  Google Scholar 

  • Thursz, M., Yallop, R., Goldin, R., Trepo, C., Thomas, H.C. (1999). Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research. Lancet, 354: 2119–2124.

    PubMed  CAS  Google Scholar 

  • Vidigal, P.G., Germer, J.J., Zein, N.N. (2002). Polymorphisms in the interleukin-10, tumor necrosis factor-alpha, and transforming growth factor-beta1 genes in chronic hepatitis C patients treated with interferon and ribavirin. Journal of Hepatology, 36: 271–277.

    PubMed  CAS  Google Scholar 

  • von Wagner, M., Huber, M., Berg, T., Hinrichsen, H., Rasenack, J., Heintges, T., Bergk, A., Bernsmeier, C., Haussinger, D., Herrmann, E., Zeuzem, S. (2005). Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology, 129: 522–527.

    Google Scholar 

  • Wiegand, J., Buggisch, P., Boecher, W., Zeuzem, S., Gelbmann, C.M., Berg, T., Kauffmann, W., Kallinowski, B., Cornberg, M., Jaeckel, E., Wedemeyer, H., Manns, M.P. (2006). Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology, 43: 250–256.

    PubMed  CAS  Google Scholar 

  • Yee, L.J., Tang, J., Gibson, A.W., Kimberly, R., Van Leeuwen, D.J., Kaslow, R.A. (2001). Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. Hepatology, 33: 708–712.

    PubMed  CAS  Google Scholar 

  • Yee, L.J., Perez, K A., Tang, J., van Leeuwen, D.J., Kaslow, R.A. (2003). Association of CTLA4 polymorphisms with sustained response to interferon and ribavirin therapy for chronic hepatitis C virus infection. Journal of Infectious Disease, 187: 1264–1271.

    CAS  Google Scholar 

  • Yoshida, H., Shiratori, Y., Moriyama, M., Arakawa, Y., Ide, T., Sata, M., Inoue, O., Yano, M., Tanaka, M., Fujiyama, S., Nishiguchi, S., Kuroki, T., Imazeki, F., Yokosuka, O., Kinoyama, S., Yamada, G., Omata, M. (1999). Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Annals of Internal Medicine, 131: 174–181.

    PubMed  CAS  Google Scholar 

  • Yoshida, H., Arakawa, Y., Sata, M., Nishiguchi, S., Yano, M., Fujiyama, S., Yamada, G., Yokosuka, O., Shiratori, Y., Omata, M. (2002). Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology, 123: 483–491.

    PubMed  CAS  Google Scholar 

  • Yoshida, H., Tateishi, R., Arakawa, Y., Sata, M., Fujiyama, S., Nishiguchi, S., Ishibashi, H., Yamada, G., Yokosuka, O., Shiratori, Y., Omata, M. (2004). Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. Gut, 53: 425–430.

    PubMed  CAS  Google Scholar 

  • Yu, M.-L., Dai, C.-Y., Huang, J.-F., Hou, N.-J., Lee, L.-P., Hsieh, M.-Y., Chiu, C.-F., Lin, Z.-Y., Chen, S.-C., Hsieh, M.-Y., Wang, L.-Y., Chang, W.-Y., Chuang, W.-L. (2007). A randomised study of peginterferon and ribavirin for 16 vs 24 weeks in patients with genotype 2 chronic hepatitis C. Gut, 56: 553–559.

    PubMed  CAS  Google Scholar 

  • Yu, M.L., Dai, C.Y., Chen, S.C., Chiu, C.C., Lee, L.P., Lin, Z.Y., Hsieh, M.Y., Wang, L.Y., Chuang, W.L., Chang, W.Y. (2003). Human leukocyte antigen class I and II alleles and response to interferon-alpha treatment, in Taiwanese patients with chronic hepatitis C virus infection. Journal of Infectious Disease, 188: 62–65.

    CAS  Google Scholar 

  • Yu, M.L., Dai, C.Y., Chiu, C.C., Lee, L.P., Lin, Z.Y., Chen, S.C., Hsieh, M.Y., Wang, L.Y., Chen, C.J., Chuang, W.L., Chang, W.Y. (2003). Tumor necrosis factor-alpha promoter polymorphisms at position -308 in Taiwanese chronic hepatitis C patients treated with interferon-alpha. Antiviral Research, 59: 35–40.

    PubMed  CAS  Google Scholar 

  • Yu, M.L., Dai, C.Y., Chen, S.C., Lee, L.P., Huang, J.F., Lin, Z.Y., Hsieh, M.Y., Wang, L.Y., Chuang, W.L., Chang, W.Y. (2004). A prospective study on treatment of chronic hepatitis C with tailored and extended interferon-alpha regimens according to pretreatment virological factors. Antiviral Research, 63: 25–32.

    PubMed  CAS  Google Scholar 

  • Yu, M.L., Dai, C.Y., Chen, S.C., Lee, L P., Hsieh, M.Y., Lin, Z.Y., Hsieh, M.Y., Wang, L.Y., Tsai, J.F., Chang, W.Y., Chuang, W.L. (2005). High versus standard doses interferon-alpha in the treatment of naive chronic hepatitis C patients in Taiwan: a 10-year cohort study. BMC Infectious Disease, 5: 27.

    Google Scholar 

  • Yu, M.L., Chuang, W.L., Dai, C.Y., Lee, L.P., Hsieh, M.Y., Lin, Z.Y., Chen, S.C., Hsieh, M.Y., Wang, L.Y., Chang, W.Y., Tsai, S.L., Kuo, H.T. (2006a). Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy. Translational Research, 148: 120–127.

    CAS  Google Scholar 

  • Yu, M.L., Dai, C.Y., Lin, Z.Y., Lee, L.P., Hou, N.J., Hsieh, M.Y., Chen, S.C., Hsieh, M.Y., Wang, L.Y., Chang, W.Y., Chuang, W.L. (2006b). A randomized trial of 24- vs. 48-week courses of PEG interferon alpha-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan. Liver International, 26: 73–81.

    CAS  Google Scholar 

  • Yu, M.L., Lin, S.M., Chuang, W.L., Dai, C.Y., Wang, J.H., Lu, S.N., Sheen, I.S., Chang, W.Y., Lee, C.M., Liaw, Y.F. (2006c). A sustained virologic response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nation-wide, multicentre study in Taiwan. Antiviral Therapy, 11: 985–994.

    CAS  Google Scholar 

  • Zeuzem, S., Feinman, S.V., Rasenack, J., Heathcote, E.J., Lai, M.Y., Gane, E., O’Grady, J., Reichen, J., Diago, M., Lin, A., Hoffman, J., Brunda, M.J. (2000). Peginterferon alpha-2a in patients with chronic hepatitis C. New England Journal of Medicine, 343: 1666–1672.

    PubMed  CAS  Google Scholar 

  • Zeuzem, S., Herrmann, E., Lee, J.H., Fricke, J., Neumann, A.U., Modi, M., Colucci, G., Roth, W.K. (2001). Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterology, 120: 1438–1447.

    PubMed  CAS  Google Scholar 

  • Zeuzem, S., Hultcrantz, R., Bourliere, M., Goeser, T., Marcellin, P., Sanchez-Tapias, J., Sarrazin, C., Harvey, J., Brass, C., Albrecht, J. (2004). Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. Journal of Hepatology, 40: 993–999.

    PubMed  CAS  Google Scholar 

  • Zeuzem, S., Buti, M., Ferenci, P., Sperl, J., Horsmans, Y., Cianciara, J., Ibranyi, E., Weiland, O., Noviello, S., Brass, C., Albrecht, J. (2006). Efficacy of 24 weeks treatment with peginterferon alpha-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. Journal of Hepatology, 44: 97–103.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hepatobiliary Division,Department of Internal Medicine, Kaohsiung Medical University Hospital, No. 100, Tzyou 1st Road, Kaohsiung 807, Taiwan

    Ming-Lung Yu

Authors
  1. Ming-Lung Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wan-Long Chuang
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Bari and National Institute for Digestive Disease, Castellana Grotte, Bari, Italy

    Emilio Jirillo

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Yu, ML., Chuang, WL. (2008). Interferon-Based Therapy for Hepatitis C Virus Infections. In: Jirillo, E. (eds) Hepatitis C Virus Disease. Springer, New York, NY. https://doi.org/10.1007/978-0-387-71376-2_9

Download citation

Publish with us

Policies and ethics

Search

Navigation